Please assess the completion status of the following clinical trial:

Trial Title: Control of COVID-19 Outbreaks in Long Term Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria for LTCHs:~  1. LTCH in Ontario with \>80% of residents being adults ≥65 years of age.~ 2. Residents are or can be routinely assessed at least daily by staff.~ 3. LTCH has not previously had a unit enrolled in this study.~ 4. Outbreak of COVID-19 declared on at least one nursing unit, requiring all of the following:~     1. ≥2 to ≤4 residents who develop PCR-confirmed symptomatic COVID-19 infection on the same unit within ≤ 7 days at the time when the outbreak is identified as eligible.~    2. ≤21 days from symptom onset in the index case at the time when the outbreak is identified as eligible.~    3. Cumulative attack rate in residents on the affected unit since the beginning of the pandemic ≤25% at the time when the outbreak is identified as eligible.~    4. ≤20% of residents with microbiologically confirmed COVID-19 or line-listed as a presumptive case in a COVID-19 outbreak and not tested for COVID-19 in prior outbreaks within the last six months.~    5. Nursing unit with ≥16 and ≤32 residents.~    6. Nursing home agrees to work with study coordination to minimize the number of persons who provide care on the unit.~ 5. Mechanism exists for delivery of medication and recording of administered medication for all residents.~ 6. ≥80% of residents on outbreak unit are eligible and they or their substitute decision makers consent to participate in the study.~ 7. Written informed consent of Medical Director, Administrator and a delegate of the Residents' Council of the LTCH for LTCH to be included in the cluster trial.~* Inclusion criteria for LTCH residents:~  1. Informed consent from resident or substitute decision maker (SDM)~* Inclusion criteria for LTCH staff:~  1. Expected to work at least two 8-hour shifts, or the equivalent time (16 hours on the unit) during the outbreak period.~ 2. Informed consent.~Exclusion Criteria:~* Exclusion criteria for LTCHs:~  1. Inability to deliver medication to consenting residents within 96 hours of identification of the outbreak.~ 2. Inability to define a physically separate unit with ≤32 residents.~ 3. Any of facility management, medical advisory committee or resident council do not approve participation.~* Exclusion criteria for LTCH Residents and Staff:~  1. Pregnancy (females \< 55 years of age require a negative urine pregnancy test at enrollment, and either menopause or two concurrent reliable methods of contraception need to be confirmed)~ 2. History of abnormalities of uric acid metabolism, other than gout.~ 3. History of hypersensitivity to remdesivir or favipiravir~ 4. Previous diagnosis of hepatic cirrhosis~ 5. Current use of the following medications, which cannot be discontinued for the duration of the study: pyrazinamide, hydralazine, more than 3000 mg of acetaminophen per day

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemoprophylaxis (Type: EXPERIMENTAL): Participants of LTCH units allocated to the chemoprophylaxis arm receive favipiravir for 25 days. Residents in the LTCH unit diagnosed with COVID- 19 at enrollment will be offered treatment with favipiravir for 14 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants of LTCH units allocated to the control arm receive placebo for 25 days. Residents in the LTCH unit diagnosed with COVID-19 at enrollment will be offered treatment with placebo for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).